il2 elisa kit  (R&D Systems)

Journal: iScience

Article Title: Interferon-α and thymosin-α1 plus tislelizumab enhance CD8 + T cell cytotoxicity toward pancreatic ductal adenocarcinoma

doi: 10.1016/j.isci.2025.113053

Figure Lengend Snippet: Influence of tislelizumab, IFN-α, and Tα1 on the surface PD-1 expression of CD8 + T cells (A) Statistical analysis of the number of CD8 + T cells at different times within 14 days after incubation with 1 μg/mL of tislelizumab with or without IFN-α and Tα1 treatment, as determined by a CCK8 assay. (B–D) Statistical analysis of the levels of the secreted cytokines IL-2 (B), TNF-α (C), and IFN-γ (D) in suspensions of cultured CD8 + T cells after incubation with 1 μg/mL of tislelizumab with or without the addition of IFN-α and Tα1 for 14 days, as assayed by ELISA. The data were analyzed by one-way ANOVA and are presented as the means ± SDs of four or five biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: IL-2 ELISA Kit , Sino Biological , Cat# KIT11848.

Techniques: Expressing, Incubation, CCK-8 Assay, Cell Culture, Enzyme-linked Immunosorbent Assay

Journal: Cancer Immunology Research

Article Title: Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells

doi: 10.1158/2326-6066.CIR-23-0902

Figure Lengend Snippet: Combination treatment of CBD and atezolizumab triggers anticancer immune response. A, MDA-MB-231 and BT20 cells were preincubated with 2.5 μmol/L CBD and 50 μg/mL atezolizumab for 1 hour and subsequently cocultured with activated Jurkat T cells at a cancer to T-cell ratio of 1:10 in the presence of a stimulator (anti-CD3/CD28) for additional 24 hours. Luciferase activity was measured using a luciferase system and microplate reader. B and C, MDA-MB-231 and BT20 cells were preincubated with 2.5 μmol/L CBD and 50 μg/mL atezolizumab for 1 hour and subsequently cocultured with activated Jurkat T cells or human PBMCs in the presence of a stimulator (anti-CD3/CD28) for additional 24 hours. Levels of IL2 ( B ) and IFNγ ( C ) were measured by ELISA assay. D–F, Human PBMC-mediated tumor-killing assay. MDA-MB-231 cells were pretreated with or without 2.5 μmol/L CBD and 50 μg/mL atezolizumab for 1 hour and cocultured with human PBMCs at the indicated effector and target cell ratio of 10:1 (effector: PBMCs; target: TNBC cells) for additional 24 hours. Human PBMCs and cell debris were washed and removed with PBS. Living tumor cells were visualized by crystal violet staining and washed with acetic acid solution. Bar graph representing the proportion of death cells is shown ( D ). The expression of cleaved (c)-PARP was determined by Western blot analysis ( E ). β-actin was used as a loading control ( F ). The proportion of apoptotic cell death in tumor cells was estimated by annexin V/PI staining by flow cytometry analysis. Data are shown as the mean ± SD and analyzed by unpaired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Article Snippet: Concentrations of IL2 and IFNγ were examined using Human IL2 ELISA Kit (DY202-05, R&D Systems) and human IFNγ ELISA Kit (DY285B-05, R&D Systems), respectively, according to the manufacturer’s instruction.

Techniques: Luciferase, Activity Assay, Enzyme-linked Immunosorbent Assay, Staining, Expressing, Western Blot, Control, Flow Cytometry